Cite

HARVARD Citation

    Drent, E. et al. (2015). Preclinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma. Journal for immunotherapy of cancer. 3 (2), p. 1. [Online]. 
  
Back to record